| Literature DB >> 32767868 |
Byunggeon Park1, Jongmin Park1, Jae Kwang Lim2, Kyung Min Shin1, Jaehee Lee3, Hyewon Seo3, Yong Hoon Lee3, Jun Heo3, Won Kee Lee4, Jin Young Kim5, Ki Beom Kim6, Sungjun Moon7, Sooyoung Choi8.
Abstract
OBJECTIVE: Lung segmentation using volumetric quantitative computed tomography (CT) analysis may help predict outcomes of patients with coronavirus disease (COVID-19). The aim of this study was to investigate the relationship between CT volumetric quantitative analysis and prognosis in patients with COVID-19.Entities:
Keywords: Coronavirus disease; Prognostic implication; Severe acute respiratory syndrome coronavirus 2; Volumetric quantitative analysis
Mesh:
Substances:
Year: 2020 PMID: 32767868 PMCID: PMC7462758 DOI: 10.3348/kjr.2020.0567
Source DB: PubMed Journal: Korean J Radiol ISSN: 1229-6929 Impact factor: 3.500
Clinical Parameter, Demographics, and Volumetric Quantitative CT Analysis according to Pneumonia Severity
| Total Cohort (n = 82) | Mild Pneumonia Group (n = 54) | Severe Pneumonia Group (n = 28) | ||
|---|---|---|---|---|
| Age (yr) | 63.1 ± 14.5 | 59.6 ± 14.4 | 69.7 ± 12.2 | 0.002 |
| Sex | 0.391 | |||
| Female | 42 (51.2) | 30 (55.6) | 12 (42.9) | |
| Male | 40 (48.8) | 24 (44.4) | 16 (57.1) | |
| Hypertension | 28 (34.1) | 12 (22.2) | 16 (57.1) | 0.004 |
| DM | 24 (29.3) | 12 (22.2) | 12 (42.9) | 0.091 |
| ESR (mm/hr) | 42.2 ± 21.7 | 38.5 ± 21.6 | 46.4 ± 21.6 | 0.255 |
| CRP (mg/dL) | 4.9 ± 6.0 | 2.7 ± 4.2 | 8.3 ± 7.0 | < 0.001 |
| WBC (cells/μL) | 5584.8 ± 2997.5 | 4929.7 ± 2828.6 | 6637.7 ± 3009.5 | 0.017 |
| Critical event | 15 (18.3) | 3 (5.6) | 12 (42.9) | < 0.001 |
| Death | 8 (9.8) | 2 (3.7) | 6 (21.4) | 0.030 |
| Total lung volume (mL) | 3457.1 ± 972.1 | 3561.1± 930.9 | 3256.5 ± 1034.7 | 0.180 |
| Emphysema % | 3.1 ± 3.2 | 3.7 ± 3.5 | 1.8 ± 1.9 | 0.001 |
| NALP (%) | 73.4 ± 14.2 | 79.7 ± 5.5 | 61.3 ± 17.6 | < 0.001 |
| CALP (%) | 8.8 ± 12.0 | 3.7 ± 4.1 | 18.6 ± 15.7 | < 0.001 |
| Emphysema volume (mL) | 123.2 ± 144.7 | 154.4 ± 160.9 | 63.0 ± 79.2 | 0.001 |
| NALPV (mL) | 2627.2 ± 985.5 | 3004.4 ± 723.3 | 1899.8 ± 1026.3 | < 0.001 |
| CALPV (mL) | 232.5 ± 229.1 | 134.0 ± 144.7 | 422.4 ± 244.2 | < 0.001 |
| F/U periods (day) | 24.3 ± 15.4 | 28.4 ± 14.7 | 16.3 ± 13.6 | < 0.001 |
Continuous variables are shown as mean ± SD and categorical variables are expressed as counts and percentage in parenthesis. CALP= COVID-affected lung proportion, CALPV = CALP volume, CRP = C-reactive protein, CT = computed tomography, DM = diabetes mellitus, ESR = erythrocyte sedimentation rate, F/U = follow-up, NALP = normally aerated lung proportion, NALPV = NALP volume, SD = standard deviation, WBC = white blood cells
Fig. 1COVID-19 infected 68-year-old male patient with CURB-65 score of 1.
(A) Non-enhanced axial chest CT, (B) CALP with green color-coded axial image, (C) color-coded axial image, (D) color-coded 3D reconstructed image. Color-coded regions of (C) and (D) were identified by HU according to following; purple, −1000 to −951 HU; blue, −950 to −901 HU; sky blue, −900 to −851 HU; green, −850 to −801 HU; yellow, −800 to −751 HU; and red, −750 to −701 HU. Total lung volume was 4318.0 mL, emphysema %; 10.3%, NALP 77.0%, emphysema volume 444.8 mL, NAPLV 3324.9 mL, and CALPV 168.4 mL. Patient was discharged alive without any ICU admission or mechanical ventilator treatment. CALP = COVID-affected lung proportion, CALPV = CALP volume, CEFS = critical event-free survival, HU = Hounsfield unit, ICU = intensive care unit, NALP = normally aerated lung proportion, NALPV = NALP volume
Fig. 2COVID-19 infected 63-year-old male patient with CURB-65 score of 3.
(A) Non-enhanced axial chest CT, (B) CALP with green color-coded axial image, (C) color-coded axial image, (D) color-coded 3D reconstructed image. Color-coded regions of (C) and (D) were identified by HU according to following: purple, −1000 to −951 HU; blue, −950 to −901 HU; sky blue, −900 to −851 HU; green, −850 to −801 HU; yellow, −800 to −751 HU; and red, −750 to −701 HU. Total lung volume was 3351.0 mL, emphysema % 2.3%, NALP 65.9%, emphysema volume 77.1 mL, NAPLV 2208.3 mL, and CALPV 656.8 mL. Patient was admitted to ICU and was placed on mechanical ventilator care; however, patient died.
Univariable and Multivariable Cox Regression Analysis for CEFS in Total Cohort
| Univariable Cox Regression Analysis | Multivariable Cox Regression Analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Age | 1.030 | 0.988–1.074 | 0.165* | Stepwise eliminated | ||
| Sex | 0.015* | 0.004 | ||||
| Male | 4.778 | 1.347–16.945 | 9.264 | 2.021–42.457 | ||
| Female | 1.000 | Reference | 1.000 | Reference | ||
| Hypertension | 0.006* | Stepwise eliminated | ||||
| Yes | 4.499 | 1.530–13.229 | ||||
| No | 1.000 | Reference | ||||
| DM | 0.174* | Stepwise eliminated | ||||
| Yes | 2.021 | 0.732–5.577 | ||||
| No | 1.000 | Reference | ||||
| ESR (mm/hr) | 0.996 | 0.971–1.022 | 0.767 | |||
| CRP (mg/dL) | 1.135 | 1.072–1.201 | < 0.001* | 1.080 | 1.010–1.156 | 0.025 |
| WBC (cells/μL) | 1.000 | 1.000–1.000 | 0.002* | Stepwise eliminated | ||
| Total lung volume (mL) | 0.999 | 0.999–1.000 | 0.033* | Stepwise eliminated | ||
| Emphysema % | 0.901 | 0.742–1.094 | 0.293 | |||
| NALP (%) | 0.936 | 0.913–0.960 | < 0.001* | Stepwise eliminated | ||
| CALP (%) | 1.066 | 1.040–1.093 | < 0.001* | 1.067 | 1.033–1.101 | < 0.001 |
| Emphysema volume (mL) | 0.998 | 0.993–1.002 | 0.321 | |||
| NALPV (mL) | 0.999 | 0.999–1.000 | 0.001* | Stepwise eliminated | ||
| CALPV (mL) | 1.005 | 1.003–1.007 | < 0.001* | Stepwise eliminated | ||
*Variables with p value < 0.2 on univariable analysis were included in multivariable analysis. CEFS = critical event-free survival, HR = hazard ratio, CI = confidence interval
Univariable and Multivariable Cox Regression Analysis for CEFS in Mild Pneumonia Group
| Univariable Cox Regression Analysis | Multivariable Cox Regression Analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Age | 1.032 | 0.919–1.160 | 0.594 | |||
| DM | 0.412 | |||||
| Yes | 3.195 | 0.199–51.228 | ||||
| No | 1.000 | Reference | ||||
| ESR (mm/hr) | 0.967 | 0.891–1.050 | 0.425 | |||
| CRP (mg/dL) | 1.204 | 1.033–1.403 | 0.018* | 1.164 | 1.006–1.347 | 0.041 |
| WBC (cells/μL) | 1.000 | 1.000–1.001 | 0.850 | |||
| Total lung volume (mL) | 0.999 | 0.998–1.001 | 0.273 | |||
| Emphysema % | 1.120 | 0.776–1.616 | 0.545 | |||
| NALP (%) | 0.954 | 0.747–1.219 | 0.706 | |||
| CALP (%) | 1.018 | 0.733–1.415 | 0.915 | |||
| Emphysema volume (mL) | 1.003 | 0.996–1.010 | 0.426 | |||
| NALPV (mL) | 1.001 | 1.000–1.003 | 0.155* | 1.001 | 0.999–1.004 | 0.295 |
| CALPV (mL) | 1.008 | 0.999–1.017 | 0.087* | Stepwise eliminated | ||
*Variables with p value < 0.2 on univariable analysis were included in multivariable analysis.
Univariable and Multivariable Cox Regression Analysis for CEFS in Severe Pneumonia Group
| Univariable Cox Regression Analysis | Multivariable Cox Regression Analysis | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Age | 0.972 | 0.931–1.015 | 0.194* | Stepwise eliminated | ||
| Sex | 0.097* | Stepwise eliminated | ||||
| Male | 3.033 | 0.819–11.238 | ||||
| Female | 1.000 | Reference | ||||
| Hypertension | 0.526 | |||||
| Yes | 1.475 | 0.443–4.909 | ||||
| No | 1.000 | Reference | ||||
| DM | 0.864 | |||||
| Yes | 1.105 | 0.356–3.432 | ||||
| No | 1.000 | Reference | ||||
| ESR (mm/hr) | 0.988 | 0.958–1.018 | 0.416 | |||
| CRP (mg/dL) | 1.069 | 0.996–1.147 | 0.063* | 1.071 | 0.984–1.164 | 0.112 |
| WBC (cells/μL) | 1.000 | 1.000–1.000 | 0.034* | Stepwise eliminated | ||
| Total lung volume (mL) | 1.000 | 1.000–1.001 | 0.554 | |||
| Emphysema % | 0.968 | 0.670–1.398 | 0.861 | |||
| NALP (%) | 0.957 | 0.926–0.989 | 0.009* | 0.872 | 0.794–0.957 | 0.004 |
| CALP (%) | 1.041 | 1.009–1.075 | 0.012* | Stepwise eliminated | ||
| Emphysema volume (mL) | 0.999 | 0.990–1.008 | 0.788 | |||
| NALPV (mL) | 0.999 | 0.999–1.000 | 0.111* | 1.002 | 1.000–1.004 | 0.019 |
| CALPV (mL) | 1.040 | 1.001–1.007 | 0.006* | Stepwise eliminated | ||
*Variables with p value < 0.2 on univariable analysis were included in multivariable analysis.